OKC pharma firm acquired in deal valued up to $665 million

If you are in a decision-making position in an Oklahoma company, is there any reason you wouldn’t want to consider doing business with a startup? You might think that there’s too much risk with a startup. Personally, I like optimism and passion. I favor businesses that stretch, that run lean, and that focus on cashflow. And I like to be part of helping a new business grow. I bet when you think about it, you do too.

If you are in a decision-making position in an Oklahoma company, is there any reason you wouldn’t want to consider doing business with a startup? You might think that there’s too much risk with a startup. Personally, I like optimism and passion. I favor businesses that stretch, that run lean, and that focus on cashflow. And I like to be part of helping a new business grow. I bet when you think about it, you do too.

Scott Rollins, CEO of Selexys Pharmaceuticals/Oklahoman photo provided by OCAST By Jim Stafford Copyright © 2017, The Oklahoma Publishing Co. Selexys Pharmaceuticals president and CEO Scott Rollins reflected on the lessons learned in the wakeRead more

A global pharmaceutical company will pay up to $665 million for an Oklahoma City research firm that recently completed a large trial of a drug that treats pain among those with sickle cell disease.

By Scott Meacham Copyright © 2016, The Oklahoma Publishing Co. As 2016 draws to a close, entrepreneurs and early stage investors in Oklahoma are ending the year with big smiles. In the past few weeks,Read more